SEC Comment Letter for Genprex, Inc. (GNPX) (CIK 0001595248) (GNPX) — Sep 1, 2017
Genprex, Inc. (GNPX) (CIK 0001595248)
Date: Sept. 1, 2017 · CIK: 0001595248 · Accession: 0000000000-17-031088
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-219386
Letter
Mail Stop 4546 September 1 , 2017 J. Rodney Varner Chief Executive Officer Genprex, Inc. 100 Congress Avenue, Suite 2000 Austin, TX 78701
Re: Genprex, Inc. Amendment No. 1 to Registration Statement on Form S -1 Filed August 18 , 2017 File No. 333-219386
Dear Mr. Varner :
We have reviewed your amended registration statement and have the following comment. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendm ent is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our August 3, 2017 letter .
Prospectus Summary Our Pipeline, page 6
1. We acknowledge your revised disclosures and response to prior comment 3. However, although you have some preclinical data, it appears that you have not identified a product candidate and/or target and therefore the program is too preliminary for inclusion in a pipeline table. Please revise to remove the program from the table. We will not object to the related narrative disclosure .
J. Rodney Varner Genprex, Inc. September 1 , 2017 Page 2
You may conta ct Frank Wyman at 202 -551-3660 or Lisa Vanjoske at 202 -551-3614 if you have questions regarding comments on the financial statements and related matters. Please contact Dorrie Yale at 202 -551-8776 or Erin Jaskot, Special Counsel, at 202 -551-3442 with any other questions .
Sincerely,
/s/ Erin K. Jaskot, for
Show Raw Text
Mail Stop 4546 September 1 , 2017 J. Rodney Varner Chief Executive Officer Genprex, Inc. 100 Congress Avenue, Suite 2000 Austin, TX 78701 Re: Genprex, Inc. Amendment No. 1 to Registration Statement on Form S -1 Filed August 18 , 2017 File No. 333-219386 Dear Mr. Varner : We have reviewed your amended registration statement and have the following comment. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendm ent is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our August 3, 2017 letter . Prospectus Summary Our Pipeline, page 6 1. We acknowledge your revised disclosures and response to prior comment 3. However, although you have some preclinical data, it appears that you have not identified a product candidate and/or target and therefore the program is too preliminary for inclusion in a pipeline table. Please revise to remove the program from the table. We will not object to the related narrative disclosure . J. Rodney Varner Genprex, Inc. September 1 , 2017 Page 2 You may conta ct Frank Wyman at 202 -551-3660 or Lisa Vanjoske at 202 -551-3614 if you have questions regarding comments on the financial statements and related matters. Please contact Dorrie Yale at 202 -551-8776 or Erin Jaskot, Special Counsel, at 202 -551-3442 with any other questions . Sincerely, /s/ Erin K. Jaskot, for Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Christopher Ozburn — Streusand, Landon & Ozburn, LLP